Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03387098 · ClinicalTrials.gov registry record · Phase 1
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
A Phase 1 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03387098 is a Phase 1 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 4 participants.
The verdict
NCT03387098, a Phase 1 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy.
Interventions
- DRUG Aldoxorubicin HCl
- BIOLOGICAL GI-4000
- BIOLOGICAL ALT-803
- BIOLOGICAL ETBX-011
- BIOLOGICAL haNK for infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-12-28 |
| Est. Completion | 2019-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03387098
The ClinicalTrials.gov registry entry for NCT03387098 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Aldoxorubicin HCl is the first listed.
NCT03387098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03387098 about?
NCT03387098 is a clinical study titled "QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy". This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy.
What is the current status of trial NCT03387098?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2017-12-28. Estimated completion is 2019-01-15.
What interventions are being tested in trial NCT03387098?
The interventions under investigation include: Aldoxorubicin HCl (DRUG), GI-4000 (BIOLOGICAL), ALT-803 (BIOLOGICAL), ETBX-011 (BIOLOGICAL), haNK for infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT03387098?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.